Syndax Pharmaceuticals (SNDX) Share-based Compensation (2015 - 2026)
Syndax Pharmaceuticals (SNDX) posted quarterly Share-based Compensation of $12.1 million for Q1 2026, up 16.12% year-over-year from $10.4 million in Q1 2025, and up 7.1% quarter-over-quarter from $11.3 million in Q4 2025.
Syndax Pharmaceuticals (SNDX) Share-based Compensation (2015 - 2026) Analysis & Trends
Syndax Pharmaceuticals' Share-based Compensation history runs 12 years deep, the most recent figure standing at $12.1 million for Q1 2026.
- In Q1 2026, Share-based Compensation rose 16.12% year-over-year to $12.1 million; the TTM figure through Mar 2026 stood at $49.2 million (up 10.49% YoY), while the FY2025 annual figure was $78.7 million, down 3.55% from the prior year.
- Share-based Compensation for Q1 2026 stood at $12.1 million, up from $11.3 million in the prior quarter.
- The five-year high for Share-based Compensation was $13.8 million in Q2 2025, with the low at $346000.0 in Q3 2022.
- The 5-year median for Share-based Compensation is $8.9 million (2024), against an average of $8.6 million.
- The sharpest annual moves came in 2022 and 2023: Share-based Compensation tumbled 89.77% in 2022, then soared 2304.91% in 2023.
- Syndax Pharmaceuticals' Share-based Compensation stood at $4.2 million in 2022, then soared by 96.35% to $8.3 million in 2023, then soared by 47.68% to $12.3 million in 2024, then slipped by 8.48% to $11.3 million in 2025, then increased by 7.1% to $12.1 million in 2026.
- Business Quant data shows SNDX's Share-based Compensation at $12.1 million in Q1 2026, $11.3 million in Q4 2025, and $12.1 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Share-based Compensation (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 108.10 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 243.00 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 277.20 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 137.41 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 590,899.88 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 86.63 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 41.25 Mn |
| 10 | Syndax Pharmaceuticals | 1.77 Bn | 1.22 Bn | 60.67 Mn | 14.01 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 14.01 Mn |
| Jun 30, 2026 | 14.01 Mn |
| Mar 31, 2026 | 12.05 Mn |
| Mar 31, 2026 | 12.05 Mn |
| Dec 31, 2025 | 11.25 Mn |
| Dec 31, 2025 | 11.25 Mn |
| Sep 30, 2025 | 12.08 Mn |
| Sep 30, 2025 | 12.08 Mn |
| Jun 30, 2025 | 13.79 Mn |
| Jun 30, 2025 | 13.79 Mn |
| Mar 31, 2025 | 10.38 Mn |
| Mar 31, 2025 | 10.38 Mn |
| Dec 31, 2024 | 12.30 Mn |
| Dec 31, 2024 | 12.30 Mn |
| Sep 30, 2024 | 11.93 Mn |
| Sep 30, 2024 | 11.93 Mn |
| Jun 30, 2024 | 9.90 Mn |
| Jun 30, 2024 | 9.90 Mn |
| Mar 31, 2024 | 8.90 Mn |
| Mar 31, 2024 | 8.90 Mn |